Stocklytics Platform
Biomea Fusion
BMEA56
$2.70arrow_drop_up1.50%$0.04
Penny Stock
BMEA56

$2.70

arrow_drop_up1.50%
Key Stats
Open$2.70
Prev. Close$2.66
EPS-4.01
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$96.39M
PE Ratio-
LOWHIGH
Day Range2.70
2.70
52 Week Range2.35
22.74
Ratios
P/B Ratio1.38
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-43.29%
EBITDA Margin %-
ROE %-104.51%
EPS-4.01
no data available for fundamentals

There's no data available for fundamentals

Stock Analysis

Stock Performance

BMEA-
US Tech-
US Market-

Biomea Fusion (BMEA) Statistics

Biomea Fusion, Inc. (BMEA) is a biotechnology company focused on developing novel targeted therapies for the treatment of cancer. The company is committed to improving the lives of patients by advancing innovative medicines that address unmet medical needs. As of the latest statistics, BMEA stock has shown positive performance in the market. With a solid valuation, the company's stock is considered to be an attractive investment opportunity. The fundamentals of Biomea Fusion, Inc. are strong, further supporting its positive outlook.
In terms of stock performance, Biomea Fusion, Inc. (BMEA) has outperformed the sector. This indicates the company's ability to generate superior returns for its investors compared to its peers in the industry. BMEA's revenue per share is impressive, reflecting its strong financial performance. The company's enterprise to EBITDA ratio, which measures its operational efficiency, is also favorable. This suggests that Biomea Fusion, Inc. is effectively managing its resources to generate profits.
add Biomea Fusion to watchlist

Keep an eye on Biomea Fusion

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Biomea Fusion (BMEA) stock's performance compared to its sector and the market over the past year?

Over the past year, Biomea Fusion (BMEA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 13.07%, Biomea Fusion has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 32.11%, it has fallen short of the market average. This comparison highlights Biomea Fusion's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Biomea Fusion (BMEA) stock?

The PE ratio for Biomea Fusion (BMEA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Biomea Fusion (BMEA) stock?

The Earnings Per Share (EPS) for Biomea Fusion (BMEA), calculated on a diluted basis, is -$4.01. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Biomea Fusion (BMEA) stock?

The operating margin for Biomea Fusion (BMEA) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Biomea Fusion (BMEA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Biomea Fusion (BMEA) is -$149.62M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Biomea Fusion (BMEA) have?

Biomea Fusion (BMEA) has a total debt of $9.57M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$78.38M.

Take Your Investments to a Whole New Level